Brought to you by 
CIS bio divests radiotherapy segment to Belgian consortium
06 Apr 2006
Executive Summary
Schering SAS, the French subsidiary of Schering AG, is selling the radiotherapy business of its CIS bio international (radiopharmaceuticals for diagnostic and therapeutic applications) subsidiary to a consortium formed by Belgian companies Ion Beam Applications SA (develops diagnostics, cancer therapies, and industrial services and equipment) and Institut National des Radioelements (produces radioisotopes).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CIS bio divests radiotherapy segment to Belgian consortium
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice